Danaher (NYSE:DHR) Price Target Raised to $250.00

Danaher (NYSE:DHR) had its price objective increased by research analysts at The Goldman Sachs Group from $210.00 to $250.00 in a research report issued on Monday. The brokerage presently has a “buy” rating on the conglomerate’s stock. The Goldman Sachs Group’s price target would suggest a potential upside of 12.72% from the stock’s current price.

Several other equities analysts have also commented on the company. Stifel Nicolaus cut their price target on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Citigroup assumed coverage on shares of Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price on the stock. UBS Group assumed coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. HSBC reduced their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $230.23.

Danaher Price Performance

Danaher stock opened at $221.80 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market cap of $155.92 billion, a price-to-earnings ratio of 39.40, a price-to-earnings-growth ratio of 2.75 and a beta of 0.78. The firm has a 50-day moving average of $205.26 and a two-hundred day moving average of $192.29. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, research analysts forecast that Danaher will post 8.53 earnings per share for the current year.

Institutional Trading of Danaher

Institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new stake in Danaher in the second quarter worth about $3,807,000. Puzo Michael J purchased a new position in shares of Danaher in the 2nd quarter valued at approximately $8,624,000. Madison Asset Management LLC acquired a new stake in Danaher in the 2nd quarter worth approximately $85,451,000. First Nebraska Trust Co purchased a new stake in Danaher during the 2nd quarter worth approximately $14,106,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Danaher during the 2nd quarter worth approximately $11,800,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.